Oridonin can effectively inhibit the mRNA and protein expression of FAS and SREBP1 in human CRC cells, subsequently reducing the transcriptional activity of the FAS promoter, which contains the sterol regulatory element binding protein 1 (SREBP1) binding site. The gene discussed is FAS; the disease is colorectal carcinoma.